Fabhalta Full Approval Strengthens Novartis Nephrology, but LOE Risks Persist

What happened

Novartis received full FDA approval for Fabhalta (iptacopan) in IgA nephropathy based on phase III data showing slower kidney function decline, bolstering its nephrology franchise. This approval adds a new growth driver to the cardiovascular-renal-metabolic portfolio, which is critical as Entresto faces rapid generic erosion (already ~35% US generic share). However, the market has already priced in strong pipeline progress, with the stock up ~47% over the past year and trading at a premium 19.5x trailing P/E. The master report maintains a POTENTIAL SELL rating, citing that the current valuation offers limited margin of safety and that 2026 guidance will test whether priority brands can offset LOE headwinds. While Fabhalta's approval is a positive catalyst, it does not change the near-term earnings risk from Entresto decline and the need for flawless execution across multiple growth assets.

Implication

Investors should view this approval as confirming the pipeline storyline but not altering the risk/reward calculus. The stock at $144 is pricing in mid-single-digit sales growth and margin recovery, leaving little room for error. Near-term catalysts (FY2026 guidance, Avidity closing) will determine if the premium is justified. We recommend trimming into strength and waiting for a better entry near $125.

Thesis delta

The Fabhalta full approval strengthens Novartis's nephrology pipeline and supports the narrative that new drugs can partially offset Entresto's decline. However, it does not change the core thesis that the stock is fully valued and vulnerable to LOE headwinds and margin dilution from M&A. The investment thesis remains bearish at current levels, with the approval adding minor upside risk but insufficient to overcome the broader risk profile.